List of Excipients in Branded Drug KOMBIGLYZE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	KOMBIGLYZE	saxagliptin and metformin hydrochloride	0310-6125	CARBOXYMETHYLCELLULOSE SODIUM
AstraZeneca Pharmaceuticals LP	KOMBIGLYZE	saxagliptin and metformin hydrochloride	0310-6125	HYPROMELLOSE 2208
AstraZeneca Pharmaceuticals LP	KOMBIGLYZE	saxagliptin and metformin hydrochloride	0310-6125	MAGNESIUM STEARATE

# KOMBIGLYZE Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Market Position

Last updated: August 22, 2026

KOMBIGLYZE XR is a fixed-dose oral combination of saxagliptin hydrochloride and extended-release metformin hydrochloride for adults with type 2 diabetes. Its commercial value depends less on novel excipients than on reliable extended-release performance, gastrointestinal tolerability, dose flexibility, and manufacturing economics. The strongest opportunities are generic substitution, lower-cost fixed-dose combinations, regional licensing, and reformulations that improve swallowability or adherence without changing the active ingredients.

What is KOMBIGLYZE and how does its formulation work?

KOMBIGLYZE XR combines two established antidiabetic mechanisms:

• Saxagliptin, a dipeptidyl peptidase-4 inhibitor.
• Metformin hydrochloride, a biguanide that reduces hepatic glucose production and improves insulin sensitivity.

The product is supplied as extended-release tablets in multiple strengths, including saxagliptin/metformin combinations of 5 mg/500 mg, 5 mg/1,000 mg, 2.5 mg/500 mg, and 2.5 mg/1,000 mg, depending on market and product presentation.[1]

The formulation challenge is the co-delivery of a low-dose, potent DPP-4 inhibitor with a high-load metformin dose. Metformin accounts for most of the tablet mass. The excipient system must therefore accommodate:

1. High drug loading.
2. Extended release over the dosing interval.
3. Chemical and physical stability of both active ingredients.
4. Consistent tablet hardness and friability.
5. Acceptable dissolution across commercial strengths.
6. Low risk of dose dumping.
7. Manufacturing throughput at large scale.

KOMBIGLYZE XR is more technically demanding than an immediate-release combination because metformin release must be controlled while saxagliptin remains uniformly distributed at a much lower concentration.

What excipients are used in KOMBIGLYZE XR?

The FDA prescribing information identifies inactive ingredients used in the KOMBIGLYZE XR tablet system. The excipient platform includes conventional pharmaceutical materials such as povidone, magnesium stearate, colloidal silicon dioxide, hypromellose, polyethylene glycol, and colorants, with composition varying by strength and tablet layer or coating.[1]

Functional role of the principal excipients

Excipient class	Typical function in KOMBIGLYZE XR-type formulation	Commercial relevance
Povidone	Binder and granulation aid	Supports tablet strength and content uniformity
Magnesium stearate	Lubricant	Controls ejection force and manufacturing friction
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend handling
Hypromellose	Matrix former or film-coating polymer	Controls release and protects the tablet surface
Polyethylene glycol	Plasticizer in film coating	Improves coating flexibility and reduces cracking
Titanium dioxide and iron oxides	Opacifying and coloring agents	Supports product identification and strength differentiation

The commercial objective is not to maximize the number of excipients. It is to establish a narrow, reproducible design space in which the excipient grades, compression conditions, coating parameters, and dissolution profile remain stable across production lots.

Which excipient attributes are critical for generic KOMBIGLYZE XR?

Generic developers will focus on excipient functionality rather than simply reproducing the branded product’s qualitative ingredient list. The critical material attributes are particle size, substitution level, viscosity grade, moisture content, bulk density, and lubricant surface area.

Extended-release polymer selection

Hypromellose is commercially attractive because it is widely available, accepted by regulators, and compatible with hydrophilic matrix systems. Its viscosity grade and particle properties influence:

• Hydration rate.
• Gel-layer thickness.
• Metformin diffusion.
• Tablet erosion.
• Dissolution sensitivity to agitation and pH.

A developer can use the same polymer family while selecting a different grade or concentration. That approach can reduce dependence on a single supplier, but it may increase bioequivalence risk if the dissolution curve changes materially.

Alternative release technologies include:

• Hydrophilic matrix tablets.
• Polymer-coated multiparticulates.
• Osmotic systems.
• Bilayer tablets.
• Compressed core-shell tablets.

The most commercially practical approach is usually a robust matrix tablet or bilayer design. Osmotic and multiparticulate systems may offer stronger release control but carry higher equipment, process-validation, and scale-up costs.

Binder and granulation strategy

Povidone can improve tablet tensile strength and reduce segregation in a high-dose metformin formulation. Wet granulation may produce better flow and content uniformity than direct compression, although it introduces drying controls and potential stability concerns.

Direct compression has lower process complexity but requires excipients with suitable flow and compactibility. For a combination product containing a low-dose saxagliptin component, segregation control is particularly important. The formulation must prevent saxagliptin-rich and metformin-rich regions during blending, transfer, and compression.

Lubrication control

Magnesium stearate is widely used but can impair tablet wetting and slow dissolution when over-lubrication occurs. Blend time, lubricant concentration, particle size, and shear history are therefore critical process variables.

A generic developer may evaluate sodium stearyl fumarate or alternative lubricants to reduce hydrophobicity. That substitution can improve dissolution in some designs, but it creates a new excipient-risk package and may require additional comparative dissolution and stability work.

What formulation patents protect KOMBIGLYZE-related technology?

KOMBIGLYZE-related intellectual property can include several layers:

1. Saxagliptin composition-of-matter patents.
2. Saxagliptin salt and crystalline-form patents.
3. Extended-release metformin technology.
4. Fixed-dose combination claims.
5. Tablet architecture and coating claims.
6. Manufacturing processes.
7. Method-of-use claims for treating type 2 diabetes.

The key distinction is between the active-ingredient patent estate and the formulation estate. A generic company may avoid a formulation patent through a different polymer system, compression process, coating composition, or tablet architecture while still needing to address active-ingredient and listed combination patents.

The FDA Orange Book is the primary source for identifying patents listed against approved KOMBIGLYZE XR products and determining whether a patent is identified as a drug substance, drug product, or method-of-use patent.[2] Patent scope must be reviewed claim by claim. An excipient substitution does not automatically avoid infringement if the claims cover broader structural or functional limitations.

When does KOMBIGLYZE lose exclusivity?

KOMBIGLYZE XR does not have biologic exclusivity because it is a small-molecule oral drug. Biosimilar risk is therefore not applicable. The relevant competitors are ANDA applicants, authorized generics, branded fixed-dose combinations, and low-cost separate-tablet regimens.

Regulatory exclusivity and patent exclusivity are separate:

Exclusivity category	Relevance to KOMBIGLYZE XR
New chemical entity exclusivity	Applied to saxagliptin’s original approval history, not indefinitely to the combination
New combination exclusivity	May apply to the original fixed-dose combination approval period
Pediatric exclusivity	Requires an FDA-listed pediatric extension, if granted
Patent exclusivity	Depends on active-ingredient, formulation, and method-of-use patents
Orphan exclusivity	Not applicable to type 2 diabetes
Biologic exclusivity	Not applicable

The exact generic-entry date depends on the surviving Orange Book patents, paragraph IV litigation, settlements, regulatory exclusivity, and any applicable pediatric extension. Commercial planning should therefore model several entry dates rather than a single assumed loss-of-exclusivity date.

What paragraph IV and litigation risks affect KOMBIGLYZE generic entry?

An ANDA applicant can file a paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[3]

For KOMBIGLYZE XR, the principal litigation risks are likely to involve:

• Whether the generic reproduces a claimed extended-release architecture.
• Whether the proposed dissolution profile falls within a claimed release range.
• Whether a formulation claim requires a particular polymer or excipient ratio.
• Whether the applicant’s label induces use covered by a method-of-use patent.
• Whether the active-ingredient patent remains enforceable in the relevant jurisdiction.

A design-around strategy is more credible when the proposed product changes both the formulation architecture and the release mechanism. Changing only a colorant, lubricant, or coating pigment generally offers limited protection against a patent claim directed to the core release system.

How strong is the KOMBIGLYZE patent estate?

The patent estate should be assessed as layered rather than treated as a single asset. Saxagliptin’s original composition-of-matter protection is historically important, but the current commercial barrier depends on remaining listed patents and enforceable claims.

Patent-strength factors

Factor	Strong position	Weak position
Claim breadth	Covers multiple release architectures or broad functional limitations	Requires narrow excipient ratios
Enablement	Supported by extensive examples and reproducible data	Limited examples or narrow formulation disclosure
Design-around difficulty	Requires extensive reformulation and clinical bridging	Can be avoided through conventional excipient substitution
Litigation history	Claims survived material validity challenges	Adverse construction or invalidity findings
Regulatory linkage	Patent is listed against the approved product	Patent is unlisted or weakly linked to the dosage form
Commercial importance	Protects the only practical once-daily combination	Protects a nonessential coating or presentation

The strongest formulation claims are generally those that link excipient composition to a reproducible release profile and pharmacokinetic result. Narrow claims directed only to a specific colorant or conventional coating ingredient are less valuable commercially.

What excipient strategies create commercial opportunities?

1. Low-cost generic extended-release tablets

The largest opportunity is a conventional ANDA product using widely available excipients and a scalable tablet process. A developer can target:

• Equivalent strengths.
• Comparable dissolution.
• Standard bottle or blister packaging.
• A limited number of manufacturing sites.
• Low-cost high-volume production.

Metformin’s large dose makes tablet size a commercial constraint. A smaller tablet can improve patient acceptance, but reducing size may require higher compression force, denser granulation, or a more efficient release polymer.

2. Improved swallowability

Large metformin-containing tablets are difficult for some patients to swallow. Commercial differentiation may come from:

• Smaller, denser tablets.
• Bilayer designs with improved mechanical efficiency.
• Film coatings that reduce friction.
• Alternative strength combinations that reduce pill burden.
• Multiparticulate capsules or sachets, where permitted.

Any redesign must preserve the extended-release profile and comply with labeling requirements against crushing or splitting if the dosage form is not designed for manipulation.

3. Lower gastrointestinal burden

Metformin commonly causes gastrointestinal adverse effects. Excipients cannot eliminate the pharmacologic cause, but release-rate control may influence tolerability. A smoother release profile, reduced peak exposure, and more predictable tablet hydration could support a differentiated product.

The commercial claim must remain within the approved labeling and regulatory evidence. A formulation change that materially alters pharmacokinetics may require more than routine comparative dissolution testing.

4. Excipient-supplier diversification

A manufacturer can reduce supply-chain exposure by qualifying multiple suppliers for hypromellose, povidone, colloidal silicon dioxide, and coating components. This has direct commercial value because shortages in a single polymer grade can interrupt production.

The substitution risk is highest for:

• Hypromellose viscosity grade.
• Metformin granule density.
• Povidone molecular-weight distribution.
• Magnesium stearate particle characteristics.
• Film-coating pigment concentration.

Supplier changes should be managed as pharmaceutical development and change-control projects, not as purely procurement decisions.

5. Regional licensing

KOMBIGLYZE XR can support licensing opportunities in markets where:

• DPP-4 inhibitors remain widely prescribed.
• Fixed-dose combinations are favored by payers.
• Metformin is the standard first-line backbone.
• Local manufacturing is encouraged.
• Generic competition has reduced prices but not eliminated demand.

A regional partner may add value through local registration, tender access, packaging, and supply-chain infrastructure. The licensor’s negotiating position improves when the formulation has documented bioequivalence, multiple qualified excipient suppliers, and a clear freedom-to-operate analysis.

How does KOMBIGLYZE compare with competing fixed-dose diabetes products?

Product category	Main advantage	Excipient and commercial implication
Saxagliptin/metformin XR	Once-daily combination with metformin	Extended-release technology and tablet size are central
Sitagliptin/metformin XR	Strong physician familiarity in many markets	Competes directly for DPP-4/metformin prescriptions
Linagliptin/metformin	Useful in selected renal populations	Different clinical positioning can reduce direct substitution
Vildagliptin/metformin	Established in several international markets	Regional pricing and registration strategy are important
Metformin plus SGLT2 inhibitor	Stronger cardiovascular and renal positioning in many guidelines	Higher clinical differentiation but often higher cost
Separate saxagliptin and metformin tablets	Flexible dosing	Higher pill burden and weaker adherence proposition

KOMBIGLYZE’s main weakness is limited differentiation against newer glucose-lowering classes, particularly SGLT2 inhibitors and GLP-1 receptor agonists. Its commercial strength is simplicity, established clinical use, and the low manufacturing cost of conventional oral tablets.

What FDA regulatory status applies to KOMBIGLYZE XR?

KOMBIGLYZE XR was approved by FDA as an extended-release saxagliptin/metformin hydrochloride combination product.[1] The relevant generic pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence, subject to applicable patent certifications and labeling requirements.

Regulatory development priorities include:

• Comparative dissolution across multiple media and agitation conditions.
• Strength proportionality or strength-specific bioequivalence justification.
• Food-effect evaluation where required.
• Stability under ICH conditions.
• Control of metformin assay and related substances.
• Saxagliptin content uniformity at low dose.
• In-vitro alcohol dose-dumping assessment where relevant.
• Manufacturing-process validation.

The FDA Orange Book should be reviewed for currently listed patents, therapeutic-equivalence codes, and approved product presentations.[2] Regulatory status can change as patents expire, delistings occur, or new generic approvals are granted.

What manufacturing and IP barriers limit commercial entry?

The largest barrier is not raw-material availability. It is the reproducibility of a high-dose extended-release combination tablet.

Key manufacturing risks include:

• Saxagliptin segregation during blending.
• Metformin granule variability.
• Excessive tablet size.
• Coating defects caused by high tablet weight.
• Dissolution drift after scale-up.
• Over-lubrication.
• Polymer-grade variability.
• Stability changes caused by residual moisture.

Intellectual-property risk increases when the proposed product uses the same matrix concept, the same functional polymer range, and a similar release profile as the branded product. A different excipient list alone may not establish freedom to operate.

What is the revenue exposure and market outlook?

KOMBIGLYZE XR’s revenue exposure is tied to the decline of branded DPP-4 products, payer pressure, and competition from newer diabetes therapies. The product remains commercially relevant as a lower-cost oral combination, but premium pricing is difficult to sustain after generic entry.

The most attractive commercial model is usually:

1. A low-cost generic launch after patent and regulatory barriers clear.
2. Multi-strength availability to capture substitution.
3. Regional licensing in price-sensitive markets.
4. Supply agreements with secondary excipient sources.
5. A differentiated formulation only where it produces a measurable adherence or manufacturing benefit.

A reformulation with a new excipient system can create value, but the added development cost must be justified by an identifiable advantage such as lower tablet mass, improved stability, reduced manufacturing cost, or a protectable release profile.

Key Takeaways

• KOMBIGLYZE XR is a saxagliptin/metformin extended-release combination tablet.
• The core formulation challenge is delivering a low-dose DPP-4 inhibitor with a high-dose metformin load.
• Hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, and coating excipients provide the main functional platform.
• Excipient substitutions can support supply-chain resilience and design-around strategies, but polymer grade and dissolution performance are high-risk variables.
• Generic entry is governed by ANDA requirements, Orange Book patents, paragraph IV certifications, litigation, and any remaining regulatory exclusivity.
• Biosimilar risk does not apply because KOMBIGLYZE XR is a small-molecule product.
• The strongest commercial opportunities are conventional generic tablets, smaller or more swallowable presentations, regional licensing, and qualified multi-source excipient supply.
• The product’s principal competitive limitation is the clinical and commercial pressure from SGLT2 inhibitors and GLP-1-based therapies.

FAQs

Can KOMBIGLYZE XR be reformulated with different polymers?

Yes. A generic developer may use a different release polymer or polymer grade if the product meets applicable pharmaceutical equivalence, bioequivalence, dissolution, stability, and patent requirements.

Which excipient is most important for KOMBIGLYZE XR release control?

The release-controlling polymer, commonly a hypromellose-type material, is generally the most important excipient for metformin release. Its viscosity grade, concentration, particle properties, and hydration behavior can materially change dissolution.

Is KOMBIGLYZE XR suitable for an authorized generic strategy?

Yes. An authorized generic strategy can use the approved formulation or a manufacturer-specific version, depending on the rights arrangement, regulatory pathway, and supply agreement. The commercial value depends on remaining brand demand and the timing of independent ANDA competition.

Can a smaller KOMBIGLYZE XR tablet receive separate patent protection?

Potentially. A smaller tablet may support formulation, composition, process, or use claims if the development produces a novel and non-obvious technical result. Conventional size reduction alone is unlikely to create strong protection.

Does KOMBIGLYZE XR have biosimilar competition?

No. KOMBIGLYZE XR contains small-molecule active ingredients. Competitive entry occurs through generic-drug pathways rather than biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2023). KOMBIGLYZE XR prescribing information: Saxagliptin and metformin hydrochloride extended-release tablets.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2024). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
5. AstraZeneca. (2011). Annual report and financial statements.